Ebrotidine (cas 100981-43-9) effect on the proteolytic and lipolytic activities of Helicobacter pylori

Add time:08/19/2019    Source:sciencedirect.com

1.1. The effect of Ebrotidine (cas 100981-43-9), a new antiulcer agent, on the activity of mucus degrading of protease and lipase enzymes elaborated by Helicobacter pylori was investigated.2.2. In the absence of ebrotidine, the H. pylori protease caused extensive degradation of gastric mucus protein, while free fatty acids, glycerol mono-oleate and lysophosphatidylcholine were produced by the action of H. pylori lipase and phospholipase A enzymes.3.3. Introduction of ebrotidine to the incubation system led to the reduction in the rate of mucus protein and lipid degradation. The rate of proteolysis inhibition was proportional to ebrotidine concentration up to 35 μg/ml at which point, a 57% reduction in mucus degradation was obtained, while the maximum inhibition of phospholipase A (96%) and lipase (93%) activities occurred at ebrotidine concentration of 60 μg/ml.4.4. The results indicate that ebrotidine is capable of counteracting the mucolytic activity of H. pylori towards protein and lipid constituents of gastric mucus layer.

We also recommend Trading Suppliers and Manufacturers of Ebrotidine (cas 100981-43-9). Pls Click Website Link as below: cas 100981-43-9 suppliers

Prev:General paperGastric mucosal laminin receptor expression with ulcer healing by Ebrotidine (cas 100981-43-9)
Next:Determination of Ebrotidine (cas 100981-43-9) and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography)